Key points:
- Subcutaneous injection of tumor microenvironment-regulated HER2 CAR lentivector-loaded lymphocytes results in the robust, in vivo proliferation of CAR+ cells that exhibit anti-tumor activity against HER2+ gastric carcinomas.
- Lymphocyte-specific fusion, internalization, and initiation of T cell activation are observed within four hours of exposure of lymphocytes to CD3-directed lentivector
- Rapid manufacturing process represents a cost-effective approach for cellular immunotherapy
